Billing & Collections Service Introduced by Acentec, TRAKnet DPM Earns Surescripts Certification — Now ARRA Certification Eligible
St. Paul, MN — May 13, 2010 — BioMedix Vascular Solutions, Inc., announced today the Surescripts certification of TRAKnet DPM Advanced Practice Management Solutions. Completing the latest Surescripts certifications positions TRAKnet DPM as a premier product, offering the latest e-prescribing features. These features include the ability to send electronic prescriptions, respond to refill requests, lookup and compare a patient’s prescription history, display pharmacy benefits and drug formulary, and suggest therapeutic alternatives. In addition, TRAKnet DPM has also been improved with other features such as a commercial drug database and drug decision support, which are necessary to comply with the pending 2011 American Recovery and Reinvestment Act (ARRA) certification.“Surescripts certification for e-prescribing has taken TRAKnet DPM, an already invaluable EHR and Practice Management solution for Podiatric Physicians, and expanded its capabilities to add even more value for our customers,” said Scott Leum, Chief Software Technologist for BioMedix. TRAKnet DPM, the expandable, all-in-one practice management platform that enables seamless operation while increasing efficiency and reducing costs, was designed by and for Podiatric Physicians. TRAKnet DPM incorporates billing, charting, scheduling, e-prescribing and inventory management to allow effortless transition from scheduling to encounters and claims while interfacing with the full BioMedix suite of software and hardware products between
physician offices, vascular labs and hospitals.“By attaining Surescripts certification to add the e-prescribing feature to TRAKnet DPM, we continue to demonstrate our commitment to supporting Podiatric Physicians with the best tools,” said John Romans, President and CEO of BioMedix.About BioMedixBioMedix Vascular Solutions, Inc. provides the only in-tegrated suite of hardware, software and online services designed to cost-effectively detect Peripheral Arterial Disease (P.A.D.) and Chronic Venous Insufficiency (CVI). Vascular specialists, primary care providers, hospitals and health systems use our products to identify these patients. Our devices and Health Information Technology (HIT) software reduce mistakes, provide data for sound analysis, build practice revenue and streamline reimbursement while providing a platform that supports the continuum of care and increased
quality outcomes.For more information about BioMedix products, call 877-854-0014 or log on to www.BioMedix.com.American College of Phlebology Preceptorship Program - New in 2010You may understand most aspects of venous disease, its causes and treatments; but are you interested in learning more about venous disease on a one-to-one basis? Are there questions you would like to ask but have not had a way to do so? The ACP Preceptorship Program can provide you with these resources – and much more.
The ACP Preceptorship Program has been designed to match physicians treating vein disease who want an
individualized learning experience with approved Preceptors in various areas of vein treatment. The goal is to enhance the provider’s knowledge in specific areas that the provider feels he/she needs. In no way does the Preceptorship Program substitute for basic venous knowledge, instead it builds on core principles in key subject areas. For more information about the program and to see if you qualify, please visit www.phlebology.org/education/preceptorships.html, or call the ACP headquarters office at 510.346.6800.
American College of Phlebology101 Callan Avenue, Suite 210, San Leandro, CA 94577 510.346.6800 www.phlebology.orgClariVein® Occlusion Catheter for Varicose Veins Wins CE Mark for Europe
Madison, Conn. May 20, 2010 — Vascular Insights announced today that it has won approval for use of the CE
Mark on its ClariVein® Occlusion Catheter, paving the way for marketing of the device in Europe.
The ClariVein® Occlusion Catheter is an infusion catheter systemintended for the treatment of incompetent veins. Infusion is through an opening at the distal end of the catheter and fluid delivery is enhancedby the use of a rotating dispersion wire to mix and disperse the infused fluid in the blood stream and on
the vessel wall.The device was certified for conformance to European standards by Notified Body BSI (the British Standards Institution). The ClariVein® Occlusion Catheter device complies with the requirements of Council Directive 93/?2/ EEC, Annex II, Section 3.2.Compared to radiofrequency or laser therapy, a key advantage of ClariVein® is that it does not require tumescence anesthesia, saving significant time and decreasing patient discomfort. In addition, a generator is not required, and therefore capital and maintenance cost is reduced.
The in-office procedure is fast and essentially pain free. Early results suggest efficacy rates equivalent to those of
radiofrequency and laser.The ClariVein® Occlusion Catheter, available only in Europe, is a product of Vascular
Insights LLC (http://vascularin-sights.com) of Madison, CT. The Company engages in the design, development, manufacture, and marketing of medi-cal devices for the minimally invasive treatment of peripheral vascular disease. Vascular Insights LLC is certified ISO 1385: 2003.Vascular Insights has named European Medical Device Distribution of Cambridge, UK, as a distributor in United Kingdom, Netherlands, Germany, Italy, Spain, Portugal, Switzerland, Austria, Czech Republic, Poland, and Turkey. The Company’s Authorized European Representative is MediMark Europe, Grenoble, France.In the United States, Vascular Insights has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) to market its ClariVein® infusion catheter, for infusion of physician-specified agents in the peripheral vasculature.Contact: Bill Kelly, HarveyMalis Communications LLC email@example.com 203-375-2696Covidien Announces Definitive Agreement to Acquire ev3 Inc. Dublin, Ireland and Plymouth, MN – June 1, 2010 – Covidien plc (NYSE: COV) and ev3 Inc. (NASDAQ:
EVVV) today announced that they have signed a definitive merger agreement under which Covidien will acquire all
of the outstanding shares of ev3 Inc. for $22.50 per share in cash, for a total of $2.? billion, net of cash acquired.
This transaction further accelerates Covidien’s strategy of building a world-class vascular platform addressing high-growth markets and positions Covidien to become a leading endovascular player, with strong positions in both the peripheral vascular and neurovascular markets.“The acquisition of ev3 will enable Covidien to significantly expand its presence in the vascular market and is in line with our strategy of becoming a leading partner with vascular surgeons, neurosurgeons, interventional cardiologists and interventional radiologists,” said Richard J. Meelia, Chairman, President and CEO of Covidien. “With its broad product portfolio, clinical expertise and call-point synergies with our existing vascular franchise, ev3 will be an important addition to our innovative vascular intervention products.”“We believe this transaction will provide truly unique opportunities and will create value for both companies’ stockholders, patients and employees,” said Robert Palmisano, President and CEO of ev3. “We will be able to advance our broad platform of peripheral vascular and neurovascular technologies with a leading global healthcare products company that shares our vision of delivering breakthrough and innovative medical solutions for improved patient outcomes. In addition, this combination will provide the opportunity for further innovation to support endovascular market growth and procedure penetration worldwide, while our employees will be afforded the opportunity to be part of a larger organization with greater depth of resources for sustained success in our industry.”ev3 Inc. is dedicated to developing innovative, break-through and clinically proven technologiesand solutions for the treatment of peripheral vascular and neurovascular diseases. ev3 offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today: peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy cath-eters and occlusion balloons.For more information, financial highlights, forward looking statements, information on the tender offer and non-GAAP financial
information, please visit http://www.ev3.net/press/news/article/?&reqid=1432551, or contact: Julie Tracy, Sr. Vice President, Chief Communications Officer, 949-680-1375, firstname.lastname@example.org.Dr. Steve Elias Voted Top Doctor “Best Vascular Surgery” for Second Consecutive YearNew York Magazine’s Thirteenth Annual, “Best Doctors” List 2010
Englewood Cliffs, New Jersey-June 11, 2010 – Steve Elias, M.D., F.A.C.S., Vascular Surgeon and the Director of The Centers for Vein Disease at both Manhattan’s Mount Sinai Medical Center and at Englewood Hospital and Medical Center in New Jersey was voted “Best Vascular Surgery” in New York Magazine’s 2010 “Best Doctors. He is the only one chosen that specializes exclusively in treating vein disease. (June 1?th issue) on newsstands now.Selected for his contributions to vein care and minimally invasive vein surgery and devotion to patient care, Dr. Elias has been chosen as one of New York’s best doctors through a peer-review process from a pool of board-certified physicians who were given an anonymous and confidential opportunity to nominate outstanding physicians in various medical specialties and sub-specialties. The process was conducted by Castle Connolly Medical Ltd.Through the nomination system, medical professionals were asked to consider and select the best doctors in each specialized field. New York Magazine published the opinions of these nominators who take into account a physician’s education, residency, board certification, hospital appointment, disciplinary record and reputation for dealing with patients of various specialties and sub-specialties.Castle Connolly Medical Ltd., a healthcare research, information and publishing company, identifies top doctors in
V E I N M A G A Z I N E S U M M E R 2 0 1 0
America and provides consumers with detailed information about their education, training and expertise through guide books and online directories. Its survey and research process, under physician management, involves outstanding doctors and the medical leadership of top hospitals. The physicians included in the special annual issue of New York Magazine are representative of the top 2 percent of New York doctors. Dr. Elias is honored to be recognized by his peers.About Steve Elias, MD, FACS Director, Center for Vein Disease; Mount Sinai School of
Medicine NY; Director, Center for Vein Disease Englewood Hospital and Medical Center NJ.Dr. Steven Elias was recently named by Vein Magazine as one of the 25 most influential professionals in vein care worldwide and Voted “Best Doctor” in 2009 and 2010 by New York Magazine. Dr. Elias lectures, publishes, and
teaches extensively about minimally invasive vein care and procedures. As Course Director of the Annual Vascular Fellows Course in Venous Disease, he trains young vascular surgeons in the treatment of vein problems. His clinical interests encompass all aspects of vein care: spider veins, varicose veins, perforator and deep venous incompetence, and venous ulcers. He performs all minimally invasive vein procedures and his work at the Center for Vein Disease includes the prevention and treatment of DVT Deep Venous Thrombosis. Dr. Elias is a fellowship-trained vascular surgeon and member of the American Venous Forum, the American College of Phlebology, the Society for Clinical Vascular Surgery, and the International Society of Cardiovascular Surgery. He is a recipient of the Dardik Research and Education Award and The Fellows Course Education Award.The American Board of Phlebology Announces Exam Dates for 2011, Results of 2010 ExamReston, VA, June 17, 2010 – The American Board of Phlebology will open their fourth phlebology exam cycle beginning in the fall of 2010.
Applications will be processed starting October, 2010, and all are to be submitted online at http://www.abph.net/application/default.asp. Prior to this date, applications will be accepted but will not be reviewed or processed until
the start of the application review period. The application submission deadline is February 11, 2011. The computer-based exam will be administered electronically between April 16 and April 23, 2011.
To become an ABPh diplomate, an applicant must complete the requisite training or experience qualifications, meet the continuing medical education requisites, and pass a stringent certification examination. Certification periods are ten years and maintenance is dependent upon the ability of the diplomate to display competency in four areas of assessment: evidence of professional standing, evidence of commitment to lifelong-learning and periodic self-assessment, evidence of cognitive expertise, and evaluation of performance in practice.
We are proud to welcome the newest class of ABPh diplomates, who successfully completed the examination this past April. There are now ?75 ABPh-certified diplomates throughout the United States and Canada, and we fully expect to pass the 500 mark with our fourth exam cycle. More information, a content outline and a directory of certified diplomates can be found at www.americanboardofphlebology.org.First Professionals Insurance Company, Inc. Endorses Medical Justice Services First Professionals Offers Medical Justice Membership as Benefit to Florida Insureds Greensboro, NC – June 15, 2010 - First Professionals Insurance Company, Inc. (First Professionals) today announced an endorsed and strategic relationship with Medical Justice
Services, Inc; the leading organization offering patented services to protect physicians’ most valuable assets – their practice and reputation – against frivolous lawsuits, Internet defamation and other medico-legal threats. Under the agreement, First Professionals will offer Medical Justice Membership to its Florida-based insureds under a preferred pricing agreement. Medical Justice’s Programs complement the traditional medical malpractice insurance offered by professional liability carriers. The agreement will provide First Professionals’ more than
7,000 policyholders in Florida, with proven, turnkey services that deliver real-world results such as decreasing malpractice suit rates, holding proponents of meritless lawsuits accountable and preventing Internet defamation.
Medical Justice focuses exclusively on the healthcare industry and has addressed the needs of doctors for over eight years. Medical Justice reports its plan members experience a statistically significant reduction in medical malpractice suits. “Medical Justice provides a variety of services that shield physicians from a number of hazards they encounter in practicing medicine. Their strategies and programs deter frivolous lawsuits,” stated Robert White, Jr., President of First Professionals. “This partnership supports and enhances First Professionals’ longstanding pledge to provide excellent benefits for all of our policyholders. Offering Medical Justice to our Florida-based insureds will be instrumental in mitigating many aggravating situations that affect healthcare providers today.”Dr. Jeffrey Segal, CEO of Medical Justice, notes, “First
Professionals is one of the most progressive malpractice insurance companies in the U.S. We are thrilled to be
endorsed by such a high-profile partner and to be part of their service offering. We aggressively address the interests of our members within the changing landscape of medical practice. By offering Medical Justice Membership to their Florida insureds, First Professionals is proactively protecting their
clients even more from frivolous medical malpractice lawsuits,
Internet defamation and other medico-legal threats.”
W W W . V E I N D I R E C T O R Y . O R G
About First Professionals Insurance Company, Inc. First Professionals has been dedicated to protecting
professional reputations and personal assets by providing medical professional liability insurance for physicians, dentists and other healthcare providers since 1975. First Professionals offers a wide variety of products and services designed to meet the unique needs of its policyholders. First Professionals is headquartered in Jacksonville, Florida, and is a subsidiary company of FPIC Insurance Group, Inc.About Medical Justice Services, Inc. Founded in 2002, Medical Justice® is a membership-based organization, run by physicians, that offers patented services to protect physicians’ most valuable assets – their practice and reputation. Our programs include affordable services to: (1) Deter frivolous malpractice claims; (2) Provide proven strategies for successful counterclaims; and (3) Prevent Internet defamation.CoolTouch Announces 5th Annual Laser Giveaway
Event at ACP Annual Meeting ROSEVILLE, Calif. (June 18, 2010) – CoolTouch will hold their 5th Annual Laser Giveaway on November 5th, 2010 in conjunction with the American College of Phlebology’s
Annual Meeting being held in Orlando, Florida November 6th-7th, 2010. Join us for educational AND entertaining
presentations and watch the finale of the evening as one lucky physician wins a CoolTouch branded laser with an estimated value of $70,000. You don’t want to miss this event!The event will be held direct-ly after the exhibitor evening reception on Friday, November 5th, 2010 from 8pm-10pm near the exhibit hall at the Renais-sance Orlando Resort at SeaWorld. Register for the laser giveaway at CoolTouch’s booth at the ACP Show.
About CoolTouch Inc.CoolTouch Inc. is a leading U.S.-based developer and manufacturer of innovative, advanced laser products for medical professionals. Engineering and science-based, CoolTouch is considered a pioneer in the medical and aesthetics technology industry. In 199?, CoolTouch introduced the first 1320 nm wavelength laser to medical professionals for non-ablative wrinkle treatment. CoolTouch continued to set new standards
in the industry with the launch of CoolTouch CTEV™ in 2006 for varicose vein treatment and with CoolLipo™ for laser lipolysis and skin tightening in 2007. More current procedures include CoolBreeze for onychomycosis
which is currently under clinical investigation. CoolTouch products are FDA-cleared and are manufactured in Roseville, Calif. For more information, please visit www.CoolTouch.com.Vein Practice Mangement Company Gets a Precision Transformation New Division Helps Doctors Put Their Best Leg ForwardVein Centers for Excellence (VCFE), a comprehensive vein practice management company serving the industry since 2001, has now become a division of Precision Practice Management (Precision) and has changed its name to Precision Vein & Vascular.
Precision is a leader in its sector of the healthcare industry, providing revenue cycle management services,
practice management and clinical (EHR) software and tech support to physician practices for the past 18 years.
Precision is currently managed by Mike Barnell, President and CEO, who describes bringing the two companies together as combining the best of what each had to offer in terms of product, service and operational efficiency and focus. Precision Vein & Vascular deploys highly qualified, dedicated resources devoted specifically to those practices specializing in the treatment of venous disease, while at the same time drawing upon the expertise and strength of Precision as its larger and broadly based parent company.Precision Vein & Vascular offers outstanding support services and guidance to vein practices for marketing (media and web-based), operations, clinical support, revenue cycle management, software (practice management and clinical), payroll, accounting, business development, network and technical support. Shelly Paule, formerly Precision’s Chief Operations Officer, has been promoted to Vice President of the Precision Vein & Vascular division, effective immediately.
Precision Vein & Vascular services to its client practices will be enhanced under Paule’s management, with support also being provided by:
• Renae Eichholz, Vice President & Revenue
Cycle Management Specialist
• Alan Pulliam, Vice President & EMR/
EHR Software Specialist
• Misty Walker-Mitra, Media &
Creative Marketing Manager
• Robert Murphy, CIO and Technical Specialist
If you’d like more information about this topic, or to schedule an interview with Shelly Paule, please call Misty Walker-Mitra at 920-202-3257 or Email at email@example.com. Total Vein Releases New Laser Fiber DesignsTotal Vein Systems, a Houston based medical supply company is pleased to announce the release of two new laser fiber designs; the Covered-Tip™ 600 and the Orb-Tip™
600 Laser Fibers. “Recently there has been a lot of interest in covered-tip fibers from physicians,” stated David Centanni, General Manager. “In an effort to meet our customers’ wants, we have expanded our product line to include Covered-Tip™ Laser Fibers.”
V E I N M A G A Z I N E S U M M E R 2 0 1 0
The new Covered-Tip™ features a glass weld at the tip of a 600 micron laser fiber that features an atraumatic design with an effective fiber diameter of 1200 microns at the distal end. The Covered-Tip™ Fiber is a high quality silicasilica fiber with low water content and a Nylon® coating. The power density is comparable to a bare tip 600 micron fiber.“Total Vein Systems strives to be on the innovative curve of the industry so we have expanded our
product line to include the new Orb-Tip™ fibers as well,” stated David Centanni. The Orb-Tip™ Fiber is comprised of a 600 micron core with a flexible outer Teflon® coating that tapers to an 800 micron, smooth spherical-ball tip.
The spherical-ball tip minimizes the chance of perforations or mechanical dissection of the vessels. In addition,
the spherical ball increases the light collection angle at the fiber tip.The introduction of these two laser fiber designs comes on the heels of the highly successful release of Total Vein’s ThermaShield™ High Performance Laser Fibers. The ThermaShield™ Fibers feature a protective layer of silica cladding to help maintain energy within the silica core, reducing carbonization and “burn back” into the outer coating of the laser fiber.
For more information contact Total Vein at 888 868-8346.Core-Spun by Therafirm® Full Calf Gradient Compression SocksTherafirm’s Core-Spun Gradient Compression Socks now with a Full Calf size to fit up to a 23” calf circumference. Core-Spun by Therafirm™ Support Socks are made with the unique technology of core-spun yarns for a patent pending, true gradient compression sock that is ultra stretchy, easier to put on, more
comfortable to wear and now available in a Full Calf size for patients with fuller lower legs. Core-Spun Gradient Compression Socks deliver a controlled amount of pressure greatest at the ankle and gradually decreases towards the top of the sock to promote better circulation, reduce swelling, and energize tired
legs and feet. Available in White, Black or Navy. Light 10-15mmHg, Mild 15-20mmHg, Moderate 20-30mmHg, and Firm 30-60mmHg Support Levels.For more information, please contact: Knit-Rite, Inc., 120 Osage Avenue,
Kansas City, KS 66105 (800) 562-2701 www.knitrite.comTCT 2010 to Have Significant Impact on Interventional Cardiology Practices and Patient Care
NEW YORK, NY -- TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.
The important role of interven-tional cardiology has figured prominently in recent current events with the announcement that former President Clinton received a heart stent in February at New York-Presbyterian Hospital,
followed by the reporting of clinical trial data showing promising results for a heart valve repair device that is inserted via a catheter.
At TCT 2010 (September 21-25 in Washington, DC), late breaking data from clinical trials on the next generation of stents, valve repair and replacement, and the interactions and effectiveness of new medicines will shed light on the best ways to treat patients. “Catheter-based valve repair and replacement, novel stents, and the effectiveness of various drugs used to treat heart disease are going to be among the major topics at TCT this year,” said Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation. TCT is organized by the Cardiovascular Research Foundation.“Non-surgical aortic valve replacement has the potential to be life saving for people who are at high risk for open heart surgery,” Stone said. “As the population ages, this technique may dramatically benefit the quality of life for patients whose aortic valves (the valve through which blood passes from the heart to the rest of the body) fail to function properly. We are hopeful that new trial data that will be presented at TCT will usher in the field of non-operative aortic valve replacement.”This year, TCT will also provide a new program, “TCT
in 3,” designed specifically for the busy interventional practitioner, which features a concentrated curriculum in a shorter 3 day time frame from Thursday, September 23 through Saturday, September 25. Highlights include live cases, late breaking trials and practice management sessions.And once again, the conference will feature specific tracks for Cardiac Surgeons and Nurses and Technologists. The Surgeons Course will provide instruction on percutaneous valve repair, hybrid (joint) surgical and interventional approaches to heart disease, percutaneous aortic aneurysm repair methods, with an in-depth course on advanced surgical techniques. The 19th Annual Nurse and Technologist
W W W . V E I N D I R E C T O R Y . O R G
Symposium will detail new trends and cath lab procedures essential for the allied health care professional.
In 2009, TCT was held for the first time in San Francisco, where it attracted record numbers of attendees. 99.?% of physician attendees surveyed stated that TCT increased their knowledge to improve their practice. Media registration is now open at www.tctconference.com. About CRFThe Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in the subspecialty of interventional cardiology and endovascular medicine.For more information, visit www.crf.org.Vascular Solutions Launches the Vari-Lase®
15 Watt Endovenous Laser Console
MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. announces the availability of the Vari-Lase® 15 Watt
Endovenous Laser Console for the treatment of varicose veins. The new Vari-Lase console incorporates several
technological innovations, including ?0% less weight, 50% smaller footprint and brighter display screen over the
original 30 Watt Vari-Lase console, but retains the open architecture SMA-905 fiber connector that allows the
physician to choose their supplier of laser fibers. Several new features were added to the Vari-Lase 15 Watt console to advance the endovenous laser procedure. A real-time readout of energy delivered, together with
programmable audio tones, assists the physician in calculating accurate pull-back rates, while the bright aiming beam, visible in both standby and ready modes, provides excellent visualization of the laser fiber tip during treatment. The new 15 Watt Vari-Lase console is now available worldwide through Vascular Solutions’ clinically trained U.S. sales force and international distributors. The Vari-Lase console is part of Vascular Solutions’ complete solution for vein practices – consisting of a full range of products for vein procedures, marketing materials for patient recruitment, and assistance in reimbursement efforts. Vascular Solutions, Inc. is a leading medical device company that delivers proprietary clinical solutions for diagnosing and treating vascular conditions. The company’s rapidly growing product line consists of innovative devices across
established and emerging areas of coronary and peripheral vascular medicine.For more information, visit www.vascularsolutions.com.Vari-Lase® is a registered trademark of Vascular Solutions, Inc.